Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2023
Reporting Period: Event date of June 14, 2023
Business Context: The Company entered into a material definitive agreement to conduct a public offering of its common stock.
Key Financial Metrics
This filing reports on a capital raising event rather than operational financial performance. Specific metrics regarding revenue, profit, cash flow, margins, debt, or liquidity are not provided in this document.
| Metric | Value |
|---|---|
| Shares to be Sold | 2,538,071 |
| Public Offering Price | $1.97 per share |
| Over-Allotment Option | Up to 380,710 additional shares (45-day option) |
| Underwriter | EF Hutton, division of Benchmark Investments, LLC |
Material Changes
The primary material change reported is the execution of an Underwriting Agreement for a public offering. This represents a significant change in the Company's capital structure and cash position upon closing, though the filing does not quantify the total proceeds or compare them to prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) regarding the offering but does not contain detailed management commentary on future operations or guidance within the text provided.
- Risks and Contingencies: The Company agreed to indemnify the Underwriters against certain liabilities, including those under the Securities Act of 1933 and breaches of representations and warranties. The filing includes standard disclaimers that representations and warranties were made for the benefit of the contracting parties and may not reflect the actual state of facts for investors.
- Unusual Items: None reported beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds of the offering, including any exercise of the over-allotment option.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and conditions precedent.
- Examine the Press Release (Exhibit 99.1) for the intended use of proceeds from the offering.
- Confirm the effective date of the Form S-1 registration statement (File No. 333-271558) referenced in the filing.